Clinical Trial Update: A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients [Phase 2]

View source ↗

Summary

This document describes a Phase 2 multicenter randomized trial comparing the standard 3+7 chemotherapy regimen to Venetoclax plus CACAG in newly diagnosed mid- …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Daunorubicin (daunorubicin)
• Venetoclax (venetoclax)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Acute Myeloid Leukemia, First Line Therapy | Phase 2 | Status: ACTIVE_NOT_RECRUITING